Date: 2013-07-15
Type of information: Licensing agreement
Compound: PSMA-specific antibody drug conjugate (ADC)
Company: ADC Therapeutics (Switzerland) BZL Biologics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
collaboration
Action mechanism: ADC Therapeutics (ADCT) specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.
Disease: PSMA-positive prostate cancer
Details: ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and BZL Biologics have announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.
ADC Therapeutics plans to initiate pre-IND development of a PSMA-specific ADC immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs. Its platform combines monoclonal antibodies specific to particular types of tumor cells, in this case PSMA, with a novel class of highly potent pyrrolobenzodiazepine
(PBD)-based warheads. As ADC Therapeutics PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.
Financial terms: Financial terms were not disclosed and remain confidential.
Latest news:
